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Abstract
The rationale for using small molecule inhibitors of oncogenic proteins as cancer therapies depends, at least in part, on the
assumption that metastatic tumors are primarily clonal with respect to mutant oncogene. With the emergence of BRAF
V600E
as a therapeutic target, we investigated intra- and inter-tumor heterogeneity in melanoma using detection of the BRAF
V600E
mutation as a marker of clonality. BRAF mutant-specific PCR (MS-PCR) and conventional sequencing were performed on 112
tumors from 73 patients, including patients with matched primary and metastatic specimens (n=18). Nineteen patients had
tissues available from multiple metastatic sites. Mutations were detected in 36/112 (32%) melanomas using conventional
sequencing, and 85/112 (76%) using MS-PCR. The better sensitivity of the MS-PCR to detect the mutant BRAF
V600E allele was
not due to the presence of contaminating normal tissue, suggesting that the tumor was comprised of subclones of differing
BRAF genotypes. To determine if tumor subclones were present in individual primary melanomas, we performed laser
microdissection and mutation detection via sequencing and BRAF
V600E-specific SNaPshot analysis in 9 cases. Six of these
cases demonstrated differing proportions of BRAF
V600Eand BRAF
wild-type cells in distinct microdissected regions within
individual tumors. Additional analyses of multiple metastatic samples from individual patients using the highly sensitive MS-
PCR without microdissection revealed that 5/19 (26%) patients had metastases that were discordant for the BRAF
V600E
mutation. In conclusion, we used highly sensitive BRAF mutation detection methods and observed substantial evidence for
heterogeneity of the BRAF
V600E mutation within individual melanoma tumor specimens, and among multiple specimens
from individual patients. Given the varied clinical responses of patients to BRAF inhibitor therapy, these data suggest that
additional studies to determine possible associations between clinical outcomes and intra- and inter-tumor heterogeneity
could prove fruitful.
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Introduction
The progression of human cancers is classically thought to
develop from a single mutated cell, followed by malignant clonal
expansion secondary to additional genetic and genomic alter-
ations. The continued acquisition of these alterations can result in
the emergence of tumor subclones with varying phenotypic
advantages (e.g. invasion, proliferation, ability to colonize different
organs, etc.) [1]. Intra-tumor heterogeneity, the presence of more
than one clone of cancer cells within a given tumor mass, and
inter-tumor heterogeneity, the presence of different genetic
alterations in different metastatic tumors from a single patient,
have been identified in several tumor types [2,3,4,5]. With the
advent of therapies targeting specific oncogenes, it is possible to
use mutation-detection strategies aimed at these oncogenes to
assess tumor specimens for inter- and intra-tumor heterogeneity.
Such heterogeneity is potentially important, as it has been shown
to affect responses to molecularly targeted treatments in cancers
such as gastrointestinal stromal tumors (GIST) and lung cancer
[3,5].
In melanoma, mutations in the BRAF oncogene are among the
most commonly reported molecular alterations [6,7], and BRAF is
currently an exciting therapeutic target. The BRAF
V600E mutation
accounts for .90% of BRAF mutations found in melanoma [8], and
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expressionincultured humanmelanomacelllinesinhibitscellgrowth
and invasion and promotes apoptosis [8,9,10,11]. Clinical trials of
selective BRAF inhibitors have shown dramatic results among
melanoma patients whose tumors possess BRAF
V600E mutation, but
not those without the mutation, highlighting the potential clinical
importance of genotyping patients’ tumors to select the appropriate
treatment [12,13,14,15]. Most recently, the BRAF
V600E inhibitor
vemurafenib was shown in a phase 3 randomized clinical trial to
improve overall and progression-free survival compared to dacarba-
zine in previously untreated patients with melanomas harboring the
V600E mutation; however, a substantial majority of patients
experience a partial response and progress by 8 months into
treatment [12].
With the emergence of targeted therapies for melanoma it may
be important to determine the extent of intra- and inter-tumor
heterogeneity among primary and metastatic tumor specimens to
further understand the pathogenesis of this disease and optimize
treatment modalities. In the current study, we analyzed a large
number of primary and metastatic melanoma tumor specimens for
BRAF intra- and inter-tumor heterogeneity using a combination
of 3 different BRAF mutation-detection assays as well as laser-
capture microdissection. We found evidence for both intra- and
inter-tumor heterogeneity of BRAF mutations within and among
multiple tumors from individual patients.
Results
Patients and Tumors
One hundred and twelve melanoma tumors were analyzed. The
study cohort consisted of 73 patients with metastatic melanoma
who contributed a total of 94 metastatic tumors and 18 primary
tumor specimens for analysis. Of the 73 patients, 46 (63%) were
Stage III and 27 (37%) were Stage IV. Tumor specimens included
42 regional lymph node metastases, 27 regional skin metastases, 18
visceral metastases, 3 local recurrences, 3 distant skin metastases, 1
distant lymph node metastasis, and 18 primary tumors.
BRAF mutation detection
To determine the presence of the BRAF
V600Emutation in the112
melanoma specimens we utilized two techniques: conventional
DNA sequencing and MS-PCR. Overall, MS-PCR detected the
mutation in a greater proportion of cases than routine sequencing
(Table 1).Using conventional sequencing we detected the
mutation in 36/112 (32.1%) cases, including 7/18 (38.9%)
primary tumors and 29/94 (30.9%) metastatic tumors. Mutation
analysis of the same melanoma specimens using MS-PCR revealed
mutations in 85/112(75.9%) cases, including 12/18 (66.7%)
primary tumors and 73/94 (77.7%) metastatic tumors, indicating
poor agreement between the two techniques (Kappa 0.23 for
comparison of sequencing and MS-PCR in detection of mutations
among metastatic specimens). Of note, there were no tumor
samples in which the mutation was detected only by sequencing
and not by MS-PCR. All mutations detected were V600E. Among
metastatic melanomas, analysis of MS-PCR mutation status by
tumor site revealed that 75% of local and regional metastases
(local recurrence, regional skin and lymph node metastases) were
mutant for BRAF, and 86.4% of distant metastases (distant skin,
lymph node, or visceral metastases) were mutant for BRAF
(p=0.26).
We previously demonstrated that the MS-PCR assay had a
greater sensitivity to detect the BRAF
V600E mutation than
sequencing [16], so one explanation for the discordance in
mutation rates between these techniques is that the presence of
contaminating normal tissue contributed to the decreased
sensitivity of mutation detection using conventional sequencing.
We investigated this possibility by estimating the tumor content of
each metastatic melanoma sample using light microscopy. This
estimation was performed without knowledge of the mutational
status of individual tumors. Cases were divided into 3 categories:
,33% tumor (n=26), 33–67% tumor (n=19), or .67% tumor
(n=49). Using MS-PCR as the gold-standard for detecting
mutations, sequencing had a sensitivity of 33% in specimens with
, 3% tumor, 29% in specimens with 33–67% tumor, and 45% in
specimens with .67% tumor (Table 2). Overall, the sensitivity of
sequencing for detecting the BRAF
V600E mutation was 39%.,
which was somewhat greater in specimens with at least 67% tumor
cells.
Laser capture microdissection to analyze intra-tumor
heterogeneity
Since the discordant results from these mutation detection
methods could not be accounted for by the presence of normal
tissue, we speculated that individual tumors may be heterogeneous
with respect to the BRAF
V600E mutation, that is, the tumors may be
comprised of a mixture of BRAF
V600E mutant and BRAF
wild-type
cells, and that only the more sensitive MS-PCR could detect low
numbers of mutant cells in certain specimens. To test this
hypothesis, we used laser capture microdissection to isolate
multiple small areas of tumor cells from each of 9 primary
melanoma tumor specimens. Each dissected tumor sample was
analyzed for the BRAF
V600E mutation via sequencing and a
mutation-specific SNaPshot assay (Figure 1). We developed this
assay to provide a relative quantification of the proportion of
mutant and wild-type alleles in a sample (see Methods for
additional details). As shown in Figure 1, there were samples in
which the mutant peak could be detected by the SNaPshot assay
but not by direct sequencing (compare sequences in panels I, J and
K to their respective SNaPshot analyses in panels N, O and P).
Other investigators have also demonstrated that SNaPshot
technology is more sensitive than sequencing in detecting
mutations in tumor specimens [17,18].
Table 1. Detection of BRAF
V600E mutations in primary and
metastatic melanomas.
Melanoma Samples (No.)
Mutations by
Sequencing
Mutations by
MS-PCR
Primary 18 7 (38.9%) 12 (66.7%)
Metastatic 94 29 (30.9%) 73 (77.7%)
Total 112 36 (32.1%) 85 (75.9%)
doi:10.1371/journal.pone.0029336.t001
Table 2. Detection of BRAF
V600E mutations in melanomas
grouped by tumor content.
Tumor Content Sequencing (%) MS-PCR (%)
,33% 8/31 (26%) 24/31 (77%)
.33%–67% 5/22 (23%) 17/22 (77%)
.67% 23/67 (34%) 51/67 (76%)
Total 36/120 (30%) 92/120 (77%)
doi:10.1371/journal.pone.0029336.t002
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PLoS ONE | www.plosone.org 2 January 2012 | Volume 7 | Issue 1 | e29336Figure 1. Representative Laser microdissection of a primary melanoma demonstrating intratumor heterogeneity of BRAF
mutations. (A) Hematoxylin and Eosin stained primary melanoma with 5 areas to be microdissected marked by squares; (B–F) Higher magnification
of microdissected areas demonstrating removal of tumor cells; (G–K) Sequencing electropherograms of the region of BRAF exon 15 in which the
T1799A mutation is found. Each sequence is derived from the microdissected tumor region immediately above it. Note the predominant green peak
of the mutant allele (A) in panels G & H, but the absence of the mutant allele in panels I, J and K; (L–P) Electropheogram peaks from the BRAF
SNaPshot analysis corresponding to the same microdissected tumor areas as the sequencing electropherograms directly above. Note the prominent
green mutant peaks in panels L & M, and the smaller but detectable mutant peaks in panels N, O and P. SNaPshot peak heights were used to estimate
percentages of mutant alleles in each microdissected sample. In this example the mutant percentages were L=81%, M=78%, N=5%, O=19% and
P=14%. See Methods for additional details.
doi:10.1371/journal.pone.0029336.g001
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of tumor cells and used the mutation-specific SNaPshot assay to
estimate the relative proportions of BRAF
V600E and BRAF
wild-type
DNA in each dissected area. We used these proportions to
calculate the overall statistical variance in BRAF
V600E DNA within
each tumor. We chose the variance as a simple measure of intra-
tumor heterogeneity for BRAF
V600E mutant cells. The relative
percentages of mutant BRAF DNA detected in the dissected
regions from these 9 tumors ranged from 0% to 81.2%. It is
important to note that the dissected areas contained between 30
and 300 tumor cells, so it is unlikely that failure to detect the
mutant allele in some regions was due to sectioning of tumor cell
nuclei. Based on the variance (6100) values and the distribution of
the data we classified the tumors into 3 categories: those in which
intra-tumor heterogeneity was ‘‘unlikely’’, those in which intra-
tumor heterogeneity was ‘‘likely’’, and those in which the intra-
heterogeneity was ‘‘marked’’ (Table 3). For example, the mutant
DNA percentages from the 5 dissected regions in tumor #9
ranged from 4.9% to 81.2%. The statistical variance6100 for this
tumor was 13.691; hence this tumor was assigned to the ‘‘marked’’
heterogeneity category. In contrast, the mutant DNA percentages
from 5 dissected regions in tumor #1 ranged from 39.4% to
56.1%. The statistical variance 6100 for this tumor was 0.419,
hence it was categorized in the ‘‘unlikely’’ heterogeneity category.
Overall, 6 of 9 primary melanomas were categorized as having
‘‘marked’’ or ‘‘likely’’ heterogeneity. This variation in the
detection of the BRAF mutation within single tumor samples
supports the hypothesis that melanomas are comprised of tumor
subclones that differ with respect to the mutational status of the
BRAF gene. It also provides an explanation for the greater
sensitivity of MSPCR versus conventional sequencing in detecting
BRAF mutations in tumor-rich samples.
Utilization of MS-PCR to investigate inter-tumor
heterogeneity in melanoma patients
Assuming that primary melanomas contain a mixture of
subclones characterized by BRAF
V600E or BRAF
wild-type cells, we
investigated whether it was the BRAF
V600E mutant clones within
the tumors that preferentially metastasized. Such an observation
would support a model in which BRAF was a driver of the
metastatic phenotype. We analyzed a set of primary and
metastatic samples from the same patient (‘matched pairs’) to
answer this question. Eighteen melanoma patients had both
primary and metastatic tumor specimens available for analysis. We
examined the concordance in mutation status, as determined by
MS-PCR, among these paired specimens. We found that 10/18
(56%) patients had tumor specimens that were concordant for the
BRAF mutation; that is, both their primary and metastatic
specimens had a mutant BRAF allele. Eight of 18 (44%) patients
had tumors that were discordant for the BRAF mutation. Six of
these 8 patients had wild-type primary tumors, but mutant
metastatic specimens, a pattern consistent with the acquisition of
the BRAF
V600E mutation conferring a growth/survival advantage
for metastases. Unexpectedly, 2/18 (11%) patients had BRAF
V600E
primary specimens but BRAF
wild-type metastases (Table 4). As the
progression to metastatic disease is generally thought to develop
through the acquisition of additional genetic alterations, one
would expect any and all metastatic tumors arising from a
BRAF
V600E primary tumor to have the same BRAF
V600E mutation.
Identification of BRAF
wild-type metastases from BRAF
V600E primary
tumors supports the concept that intra-tumor heterogeneity of
BRAF
V600E mutant cells exists within primary melanomas.
Assuming that both BRAF
V600E and BRAF
wild-type cells could give
rise to metastatic tumors, we used MS-PCR detection of the
BRAF
V600E mutation to investigate inter-tumor heterogeneity
between multiple metastatic tumors from individual patients.
Nineteen patients had multiple metastases available for analysis,
and a total of 40 metastatic specimens were studied. In 13/19
(68%) patients, all analyzed metastases were mutant; 1/19 (5%)
patients had two wild-type metastases. Surprisingly, 5/19 (26%)
patients had metastases that were discordant for the BRAF
V600E
mutation. These patients had both mutant and wild-type
metastatic tumors (Table 5). Taken together, these data and the
analysis of the primary tumors suggest that many primary
melanomas are heterogeneous with respect to the BRAF
V600E
mutation, and that some of the metastasizing tumor subclones do
not require the presence of the BRAF mutation.
Discussion
The recent success of BRAF
V600E kinase inhibitors in melanoma
has been dramatic; however, enthusiasm has been tempered by
the heterogeneity and relatively short duration of patients’
Table 3. Detection of intratumor variation in BRAF mutation rates via laser capture microdissection.
Tumor
No. regions
dissected BRAF
V600E DNA percentages
Statistical variance
(6100)
Presence of
heterogeneity
1
Dissected region
1 2 3 4 5
1 5 39.4% 42.8% 43.6% 48.1% 56.1% 0.419 Unlikely
2 4 7.4% 13.4% 16.3% 31.3% 1.038 Unlikely
3 3 6.7% 7.9% 29.0% 1.575 Unlikely
4 3 0.0% 16.8% 33.4% 2.787 Likely
5 4 0.0% 21.9% 32.5% 39.7% 2.991 Likely
6 4 9.7% 42.5% 52.9% 53.6% 4.247 Marked
7 4 0.0% 0.0% 22.2% 48.3% 5.286 Marked
8 4 0.0% 0.0% 0.0% 48.9% 5.969 Marked
9 5 4.9% 13.9% 18.8% 77.7% 81.2% 13.691 Marked
1Qualitative judgment based on variance values, see text for full explanation.
doi:10.1371/journal.pone.0029336.t003
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ably high response rates of 60% to 80% in melanoma patients with
advanced metastatic disease whose tumors harbor the BRAF
V600E
mutation. There is a subset of patients, however, whose tumors
harbor the mutation yet fail to achieve any significant response to
therapy. Even among patients who benefit from BRAF inhibitors,
responses, albeit profound, are generally short-lived. Resistance to
the inhibitor vemurafenib, for example, usually develops within 8
months [12,13].
To improve our understanding of melanoma biology and
develop effective, personalized treatment options it is important to
determine the degree to which primary and metastatic tumors
result from the emergence of a dominant clone of tumor cells, or
are comprised of several different malignant tumor cell clones. A
recent analysis of 3 breast cancer tumors using single nucleus
sequencing provides a striking example of the polyclonal nature of
some primary and metastatic tumors [19]. Here we report an
investigation of intra- and inter-tumor heterogeneity in melanoma
using the presence of a single oncogene mutation to define the
presence of a clonal population of tumor cells. We analyzed the
BRAF
V600E mutation because it is the most frequently detected
mutation in melanoma, it has been studied extensively in pre-
clinical models as a driver of the malignant phenotype(reviewed in
[20]), and understanding its role in melanomagenesis is highly
relevant to current clinical trials with BRAF and MAPK pathway
inhibitors. Using a combination of very sensitive assays for
detecting BRAF mutations, including laser-capture microdissec-
tion, we found substantial evidence for the presence of intra-tumor
heterogeneity in primary melanomas and inter-tumor heteroge-
neity between multiple metastatic tumors from individual patients.
Using MS-PCR we observed a substantially higher rate of BRAF
mutation in primary and metastatic melanoma tumor specimens
compared to sequencing. These mutation rates are comparable to
previously reported rates in melanoma [8,21,22,23,24,25,26,27].
One explanation for the greater sensitivity of MS-PCR to detect
the BRAF
V600E mutation is that it is an allele-specific PCR that
requires very little mutant template to return a positive result
[16,28]. Our previous work demonstrated that the sensitivity of
routine sequencing to detect the BRAF
V600E mutation diminishes
as the proportion of BRAF
wild-type DNA is a sample rises, but the
sensitivity of the MS-PCR is unaffected [16]. Given these assay
characteristics we expected the detection rates of sequencing to
approach those of the MS-PCR in tumor-rich samples. Surpris-
ingly, there was a marked discordance in the detection rates
between the two methods even in these tumor-rich samples. This
finding led us to speculate that the difference in the detection rates
between DNA sequencing and MS-PCR was not due solely to the
presence of contaminating normal tissue, but perhaps due to the
presence of multiple tumor subclones within individual tumor
specimens, some of which were BRAF
wild-type while others were
BRAF
mutant.
We directly tested this hypothesis of intra-tumor heterogeneity
using laser-capture microdissection combined with SNaPshot
technology allowing semi-quantitative assessment of BRAF
V600E
and BRAF
wild-type alleles. We found that a substantial proportion of
individual tumor specimens contained a mixture of BRAF mutant
and wild-type melanoma cells. This finding is consistent with
recent data analyzing acquired melanocytic nevi, benign neo-
plasms of the melanocytic lineage that frequently possess the
BRAF
V600E mutation. Using single-cell PCR analysis, Lin et al.
demonstrated that BRAF
V600E mutations could be detected in
different cells within the same nevus [29]. Our results are also in
agreement with their more recent findings that melanomas also
display intratumor heterogeneity with respect to BRAF
V600E
mutations. They performed single-cell PCR and sequencing of
40–56 cells from each of five primary melanomas and found that 4
Table 4. BRAF mutation concordance between primary and
metastatic specimens using MS-PCR.
Patient Primary tumor Metastatic tumor
1 Wild Type Mutant
2 Wild Type Mutant
3 Wild Type Mutant
4 Wild Type Mutant
5 Wild Type Mutant
6 Wild Type Mutant
7 Mutant Mutant
8 Mutant Mutant
9 Mutant Mutant
10 Mutant Mutant
11 Mutant Mutant
12 Mutant Mutant
13 Mutant Mutant
14 Mutant Mutant
15 Mutant Mutant
16 Mutant Mutant
17 Mutant Wild Type
18 Mutant Wild Type
doi:10.1371/journal.pone.0029336.t004
Table 5. BRAF mutation concordance between multiple
metastatic specimens using MS-PCR.
Patient Metastasis 1 Metastasis 2
19 Wild Type Wild Type
9 Wild Type Mutant
20 Wild Type Mutant
21 Wild Type Mutant
22 Wild Type Mutant
23 Wild Type Mutant*
2 Mutant Mutant
6 Mutant Mutant
14 Mutant Mutant
15 Mutant Mutant
24 Mutant Mutant
25 Mutant Mutant
26 Mutant Mutant
27 Mutant Mutant
28 Mutant Mutant
29 Mutant Mutant
30 Mutant Mutant
31 Mutant Mutant*
32 Mutant Mutant
*patient had a third metastasis which was mutant by MS-PCR.
doi:10.1371/journal.pone.0029336.t005
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wild-type and
BRAF
V600E tumor cells. They supported this finding with an
analysis of 10 additional melanomas using a more sensitive
mutation detection assay and subcloning [30].
Although BRAF mutation is not required for the formation of all
nevi and melanomas, it is a commonly held assumption that when
present, BRAF mutations are a very early mutational event that
cooperates with additional alterations in growth control genes to
drive melanomagenesis. Together, the findings in the current
study and the published data suggest a more complex picture
characterized by both intra-tumor heterogeneity of primary
melanomas and inter-tumor heterogeneity among metastatic
tumors. Many primary melanomas appear to be comprised of at
least 2 malignant subclones that differ with respect to their BRAF
genotype (mutant or wild-type). Thus, mutations in BRAF do not
appear to be an initiating event for all cells in a given nevus or
melanoma, even those neoplasms in which the mutation can be
detected, as it may be present in only a subset of tumor cells. In
addition, our analysis of a set of matched primary and metastatic
tumors from individual patients further suggests that BRAF
mutations may not be required for development of metastasis in
BRAF
V600E-mutant primary melanomas. We observed that two
primary melanoma tumors containing BRAF
V600E mutations gave
rise to metastases that were BRAF
wild-type. Additionally, in 5 patients
with multiple metastases, separate metastases from the same
patient were found to be discordant with respect to BRAF
mutation status using the highly sensitive MS-PCR assay. Based
on these findings, it appears that primary melanomas may contain
a heterogeneous mixture of BRAF
V600E and BRAF
wild-type tumor
cells, and it is possible for both populations to give rise to
metastases. This model is supported by an interesting report from
Sensi et al in which the investigators were able to isolate, via single
cell cloning, separate populations of BRAFV600E/NRASwild-
type and BRAFwild-type/NRASQ61R melanoma cells from a
single metastatic tumor [31].
Intratumor heterogeneity has been recognized as a general
characteristic of many cancers. Importantly, it is becoming
apparent that the efficacy of, and resistance to molecularly
targeted therapies may be dependent upon the presence of
genetically distinct tumor subclones. For example, a study of
intratumor heterogeneity of EGFR mutations in non-small-cell
lung cancer found that tumors that contain both mutation-positive
and mutation-negative tumor cells are less responsive to gefitinib
than tumors that do not display such heterogeneity [5]. To date,
studies of BRAF resistance in melanoma have identified several
mechanisms that bypass the pharmacologic block of mutant
BRAF. Two of these mechanisms: 1) upregulation of COT a
member of the Ser/Thr MAP3K kinase family that functions
downstream of BRAF; and 2) mutation of NRAS, result in
activation of the MAPK proliferation pathway [32,33]. The NRAS
mutation findings [33] are particularly interesting from the
perspective of tumor heterogeneity. First, the two different NRAS
mutations identified by the group were found in two distinct
BRAF-resistant post-treatment nodal metastases from the same
patient. This finding supports the concept that separate metastases
within a single patient may be driven by different subpopulations
with distinct molecular alterations, as our study suggests. Secondly,
examination of the sequencing electropherogram for the sample
with the mutated NRAS
Q61K allele (their supplemental figure 14)
reveals that the NRAS mutant allele appeared to be present in a
very small population of cells, based on the heights of the mutant
versus wild-type peaks and the investigators inability to detect the
mutant peak in 3/6 macrodissected regions of the tumor
specimen. In comparison, sequencing of BRAF in short-term
cultures from the same tumor revealed an easily detected mutant
peak, suggesting that more than half of the tumor was comprised
of BRAF mutant cells. This suggests that a large proportion of
BRAF mutant cells in the resistant tumor did not harbor the NRAS
mutation.
Since the mutant form of NRAS can bypass BRAF inhibition
[34,35,36,37,38,39], it is surprising that such a small percentage of
BRAF
mutant cells carrying the NRAS mutation would be sufficient for
conferring treatment resistance. One explanation may be that
multiple mechanisms of secondary resistance allow for the
concomitant survival of the BRAF
mutant cells that were wild-type
for NRAS (e.g. activation of PDGFR [33]). Indeed, there is
published evidence that heterogeneity can evolve both within and
between tumors from the selective pressures of molecularly
targeted therapies. An analysis of separate metastatic gastrointes-
tinal stromal tumors from individual patients to identify drug-
resistance mechanisms revealed different secondary mutations in
different tumors, and even found multiple secondary mutations
within the same metastasis [3]. In addition, a recent study of
resistance in ovarian carcinoma to platinum-based chemotherapy
has supported this model of multiple, intrinsically resistant
subclones present at initial tumor presentation, prior to treatment
[40].
As mechanisms of resistance to BRAF inhibitor therapy
continue to be uncovered, it will be prudent to consider the
implications of intratumor heterogeneity on treatment response
and management. The potential presence of heterogeneity among
metastatic tumors suggest that relying on a single biopsy specimen
for treatment decisions with BRAF inhibitors could exclude some
patients who would benefit from the therapy. These patients
essentially have a ‘‘false negative’’ biopsy result, as different, non-
biopsied metastatic tumor sites may harbor a BRAF mutation
[41,42]. Genotyping a second tumor specimen from a patient
whose initial results are negative for the V600E mutation may
reduce the possibility for such ‘‘false negative’’ genotyping results.
An alternative genotyping approach being explored by our group
is the use a blood-based mutation-detection method that would
assay DNA shed from all metastatic sites, not just a single tumor.
This approach could potentially expand the pool of patients
eligible for these drugs.
Another implication of the results described here is the
possibility that very small populations of NRAS
mutant/BRAF
wild-type
tumor cells may co-exist with BRAF
mutant tumor cells within the
same patient. This possibility is further supported by recent data
from a large retrospective study of BRAF and NRAS genotyping
results demonstrating a small fraction of patients in which both
BRAF and NRAS mutations were detected in their tumor specimen,
possibly due to intratumor heterogeneity [43]. The co-existence of
BRAF
mutant and NRAS
mutant tumor cells has potential clinical
implications as in-vitro studies have demonstrated that pharma-
cologic inhibition of wild-type BRAF in the presence of oncogenic
RAS can promote melanoma proliferation and/or resistance to
apoptosis [34,35,36,37,38,39]. Presumably the treatment of
patients with a mixed population of tumor cells could result in
the rapid development of treatment resistance as has been
observed in some patients. As activation of the MAPK pathway
appears to be one of the critical elements contributing to
melanoma cell proliferation and survival [38,44] current strategies
to combat resistance to BRAF inhibitor therapy are focused on
combination therapies that simultaneously target more than one
component of the MAPK pathway, such as BRAF and MEK
(NCT01072175). Given the potential activating effects of BRAF
inhibition in the presence of oncogenic NRAS, and the potential
for mutations in downstream pathway members such as MEK1
Heterogeneity of BRAF
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among tumor specimens both before treatment and upon disease
recurrence to more fully understand the development of resistance
to targeted therapies.
In conclusion, data from the current study and the published
literature support a model in which individual melanoma tumors
can be polyclonal, that is, comprised of a mixture of cells that may
or may not have the BRAF
V600E mutation, with both populations
having the ability to metastasize. These findings warrant further
study in the context of melanoma tumor progression models, and
whether the degree of intratumor heterogeneity in patient tumors
could influence the efficacy of molecularly targeted therapies
directed against mutant BRAF. The growing body of evidence
demonstrating intratumor heterogeneity within solid tumors,
including melanoma, suggests that selecting the optimal therapeu-
tic regimen for melanoma patients may ultimately hinge on
characterizing tumors based on the precise genetic makeup of
tumor subclones.
Materials and Methods
Ethics Statement
The study was approved by the New York University School of
Medicine Institutional Review Board, and all patients signed
written informed consent at time of enrollment.
Patients and Tumor characteristics
Melanoma patients were prospectively accrued in the New York
University School of Medicine Interdisciplinary Melanoma
Cooperative Group database. Patients had either stage III or IV
disease at time of enrollment. Patients were selected based on the
availability of clinical specimens, and all available tumor tissue
from each patient was included in this study. Laser capture
microdissection and BRAF T1799A SNaPshot analysis was
performed on 9 primary melanoma tumors that were selected
out of convenience, that is, tumor blocks were readily available for
the tissue sectioning required for laser capture microdissection.
Mutation detection using whole tissue sections
Unstained cut sections mounted on slides were scraped into 1.5-
ml microcentrifuge tubes. Subsequent steps followed the protocol
for DNA isolation from paraffin slides in the QIAmp Mini Blood
DNA kit (Qiagen, Valencia, CA). For each melanoma tumor,
hematoxylin and eosin-stained slides were reviewed to ensure
enough viable tumor, and each slide was scored for tumor content
by two investigators (DP and MY) to estimate the percent of tumor
nuclei to all nuclei in the sample. Scores were defined as ,33%
tumor, 33%–67% tumor, and greater than 67% tumor. The
investigators were blinded to the mutation results at the time of
assessment of tumor content. For conventional sequencing,
amplification of the entire BRAF exon 15 was accomplished as
previously described, using primers designed by Davies, et al.
[8,22]. Mutant-specific polymerase chain reaction (MS-PCR) was
performed as previously described [16]. In addition, DNA from
the human melanoma cell line SK-MEL 29 (mutant for BRAF) was
used as a positive control, and human placental DNA was the
negative control.
For the MS-PCR all tissue specimens were run in duplicate. In
the event of discordant results, mutation status was determined by
a third run. There were 20 cases in which there was discordance
between the initial 2 MS-PCR reactions. Of these, 10 cases
resulted in a positive mutation call on the subsequent run, and 10
cases resulted in a wild-type call. Each run was accompanied by a
dilutional series of control DNA ranging from 0.001 ng SK-MEL
29 to 10 ng SK-MEL 29 in triplicate as a quality control measure
of assay sensitivity. Human genomic placentalDNA (Sigma-
Aldrich, St. Louis, MO), wild type for BRAF, and water were
included in every run in triplicate as negative controls.
Laser capture microdissection
Freshly cut 10 micron paraffin-embedded sections from nine
primary melanomas were placed onto polyethylene naphthalate
(PEN) membranes that were mounted onto glass slides (Leica,
Wetzlar, Germany). Sections were stained with hematoxylin and
eosin (H&E) for 30 minutes to allow for visualization of nuclei and
cytoplasm and maintained without cover slips as required for laser
capture microdissection (LCM). Cover-slipped H&E slides previ-
ously cut from the same block of tissue were examined using light
microscopy to identify tumor rich regions lacking invading
lymphocytes or interspersed fibrous stroma which could contain
contaminating normal fibroblasts. Laser-assisted microdissection
of melanoma cells was performed using the Leica Microsystems
LMD7000 laser capture microdissection system. The smallest
dissected area measured approximately 1500 mm
2, the largest
approximately 15,000 mm
2, corresponding to approximately 30 to
300 cells in each dissected section. A minimum of 3 and a
maximum of 5 dissected areas were obtained from each case; in 5/
9 (56%) cases 4 areas were dissected. DNA was extracted and
purified from each dissected area separately using the Qiagen
QIAmp DNA micro kit according to the manufacturer’s
instructions. Purified DNA was used as a template to amplify
BRAF exon 15 using the following primers: 59- AGTAACTCAG-
CAGCATCTCAGG and 59-ATCTCTTACCTAAACTCTT-
CATAATGC. This set of primers creates a 273 bp amplicon,
which was used for sequencing and mutation detection using
SNaPshot technology.
Use of SNaPshot technology to detect BRAF T1799A hot-
spot mutation. Amplified BRAF PCR products were purified
using PCR Clean-up Kits (Roche Molecular Biochemicals,
Indianapolis, IN) and subjected to SNaPshot reaction according to
the manufacturer’s instructions (Applied Biosystems, Foster City,CA)
using the following probe: 59-CACAGTAAAAATAGGTGA-
TTTTGGTCTAGCTACAG. The products of the SNaPshot
reaction were examined via gel-capillary electrophoresis using an
Applied Biosystems ABI310 genetic analyzer and data was
interpreted using Genemapper software (Applied Biosystems). The
percentage of mutant allele was calculated by the following formula:
% mutant allele~ PMUT
PMUTzPWT  
|100
where P
MUT is the peak height of the mutant allele and P
WT is the
peak height of the wild-type allele.
Based on the distribution of the data, we grouped the cases into
3 categories. The cases with the 3 lowest variances were grouped
into a category in which substantial tumor heterogeneity was
unlikely (variances=0.419, 1.038, and 1.575, respectively). The
case with the next highest variance (Case #4) had a value that was
nearly double the value of specimen with the highest variance in
the ‘‘unlikely’’ category. Therefore, we grouped Case #4 and
those with higher variance values into the category where
substantial tumor heterogeneity was likely or even marked.
Statistical Analysis
Descriptive statistics were calculated for demographic and
clinicopathologic characteristics. The concordance (agreement)
between direct sequencing (wild type/mutant) and MS-PCR (wild
type/mutant) was assessed by the kappa statistic. The sensitivity
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PLoS ONE | www.plosone.org 7 January 2012 | Volume 7 | Issue 1 | e29336and specificity of direct sequencing, utilizing MS-PCR as the gold
standard, were estimated to examine the false positive and false
negative rates of direct sequencing. The assessment of agreement
between direct sequencing and MS-PCR was also stratified by
tumor content (,33%, 33–67%, and .67%). The chi-square test
was used to assess the relationship between tumor site (local/
regional vs. distant) and MS-PCR mutation status (wild type/
mutant). All p-values are two-sided with statistical significance
evaluated at the 0.05 alpha level. Ninety-five percent confidence
intervals (95% CI) were calculated to assess the precision of the
obtained estimates. All analyses were performed in SAS Version
9.1 (SAS Institute Inc., Cary, North Carolina) and Stata Version
10.0 (StataCorp, College Station, Texas).
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